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Pelvic bone metastases are a growing concern in the field of orthopedic surgery. Patients with pelvic metastasis are individually
different with different needs of treatment in order to attain the best possible quality of life despite the advanced stage of disease.
A holistic collaboration among the oncologist, radiation therapist, and orthopedic surgeon is mandatory. Special attention has to
be directed to osteolytic lesions in the periacetabular region as they can provoke pathological fractures and subsequent functional
impairment. Different reconstruction techniques for the pelvis are available; the choice depends on the patient’s prognosis, size of
the bone defect, and response of the tumor to adjuvant treatment. If all the conservative treatments are exhausted and the patient
is not eligible for surgery, one of the various percutaneous ablation procedures can be considered. We propose a pelvic analogue
to the treatment algorithm in long bone metastasis and a scoring system in pelvic metastasis. This algorithm aims to simplify the
teamwork and to avoid under- or overtreatment of pelvic bone metastases.
1. Introduction
Primary cancer can spread via the blood or lymphatic
circulation to distant organs and form ametastasis. In theory,
any organ of the body can be affected, but after lung and liver,
bone is the third most common site for metastases. Prostate
(32%), breast (22%), kidney (16%), lung and thyroid cancer
have a high risk for metastatic bone disease. In fact, these
primary carcinomas account for 80% of all the metastases to
the bone [1].
Metastatic lesions are found most frequently in the
spine, followed by the pelvis. Indeed 833 (18.8%) of all 4431
metastatic lesions registered in the archive of the Rizzoli
institute [2] were found to occur in the pelvic region: 559
(12.6%) are located in the ilium, 80 (1.8%) in the ischium, and
53 (1.2%) in the pubis.
In most of the cases complete cure of the disease is not
possible and treatment is aimed at palliation. Nevertheless,
metastatic carcinoma to the pelvis and the acetabulum
decreases seriously the quality of life of the patient and
necessitates further treatment. Surgical intervention helps to
achieve adequate pain control and to prevent or stabilize
pathological fractures. However, in selected cases, complete
resection may improve the survival rate of the patient.
The overall prognosis of patients with bone metastasis is
extremely variable depending on the site of the lesion, type of
primary carcinoma, and existence of further metastasis.
In the past decades, the life expectancy of patients with
metastatic carcinoma has improved considerably because
of advances in chemotherapy, immunotherapy, hormonal
treatment, and radiotherapy [3]. However, this has resulted in
an increase in number of patients at risk of developing bone
metastases or experiencing a pathological fracture [4]. These
patients demand a more reliable and stable reconstructive
technique.
Myeloma and lymphoma bone lesions have been shown
to have a similar biological behavior as metastatic bone
disease and the mechanical implications are comparable.
However, chemotherapy and radiotherapy are still the corner-
stones of treatment for all lymphomas. In lymphoma patients,
bone lesions at risk for a fracture are often successfully treated
with chemotherapy and radiotherapy in combination with
rest and non-weight-bearing. Surgery is only indicated in
pathological fractures with major functional impairments,
whereas the timing remains a controversial issue [5]. If
fracture location and patient condition allow, the surgical
treatment can even be delayed until chemotherapy and radia-
tion therapy are finished [5]. In summary, surgical treatment
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Figure 1: Anatomic regions of the pelvis according to the Enneking
classification.
of primary bone lymphoma should aim to restore function
and pain while minimizing potential delay in chemotherapy
initiation.
To date, there is no officially accepted treatment algo-
rithm for pelvic bonemetastasis. Orthopedic surgeons, onco-
logists, or radiotherapists have been treating pelvicmetastasis
without any guidelines to consider the indications for surgical
treatment. The following overview discusses the different
possible surgical techniques and their indications and lim-
itations in dealing with pelvic bone metastasis. The chosen
procedure should offer an adequate treatment to the patient
to achieve the best possible quality of life while avoiding
under- or overtreatment.
2. Anatomic Regions of the Pelvis
Metastatic lesions affect the strength of bone reducing stress
transmission and the ability to absorb energy. The evaluation
of the risk of fracture in a metastasis of the pelvis is guided by
its appearance and its location.
Osteolytic lesions are more at risk of fracture than osteo-
blastic or mixed lesions. Those with a permeative pattern
of osteolysis have the same risk of fracture as the more
classic types, which show a discrete area of lysis. Permeative
osteolysis may be underestimated on plain radiographs, but
MRI usually reveals the real extent of the disease.
Highly stressed anatomical sites are particularly predis-
posed for pathological fractures. According to the Enneking
classification [6] the pelvic girdle is divided into 4 different
regions as shown in Figure 1.
Zones 1 and 3 are comparable to non-weight-bearing
and expendable bones of the extremity and trunk (clavicle,
sternum, and fibula). Zone 2 equates to the articular part of
major long bones (humerus, femur, and tibia).
The periacetabular (zone 2) lesions are at greater risk for
mechanical failure with progressive destruction of the hip
joint. Metastatic lesions in zones 1 and 3, even if they are
osteolytic, do not compromise the mechanical stability of the
pelvic ring.
3. Patient Classification
The multidisciplinary approach to bone metastasis needs a
good functioning interaction between orthopedic surgeon,
oncologist, and radiotherapist, especially when surgery is
needed. Capanna and Campanacci [7] introduced in 2001
an algorithm in long bone metastases providing an easy tool
for all involved specialists to find an adequate treatment. The
patients are divided into 4 classes: (1) solitary lesionwith good
prognosis; (2) pathologic fracture; (3) impending fracture;
(4) other lesions (see Table 1). In selecting the adequate
treatment in long bones and pelvis, important parameters as
expected survival, the type and stage of the tumor, visceral
spread, the time interval from the primary lesion, the risk
of pathological fracture, and the sensitivity to chemotherapy,
hormone therapy, and irradiation are considered.
4. Guidelines for Multidisciplinary Treatment
The treatment depends on the patient’s prognosis (Capanna
Classes 1–4), the exact site of the metastasis in the pelvis
(Enneking zones 1–3), and the amount of bone loss of the
periacetabular region. A schematic overview of a proposed
treatment algorithm is given in Figure 2.
All patients in Classes 1, 2, and 3 should have priority
referral to an orthopedic oncologist for surgical treatment.
After the operation they will be sent back to an oncologist
and a radiotherapist for the evaluation of adjuvant treat-
ment. Patients in Class 4 are treated first conservatively by
chemotherapy, hormone therapy, and/or radiation therapy.
5. Patient Class 1
Class 1 includes those patients with a single metastatic lesion
of a primary tumor with a good prognosis and an interval of
more than three years from detection of the primary lesion
to the development of bone metastasis. Primary tumors with
a favorable prognosis include well-differentiated thyroid,
prostate, breast, when sensitive to hormonal treatment or
chemotherapy, clear-cell renal, and colorectal carcinoma.The
metastasis is treated as a primary tumor and the operation
aims to achieve a long-term cure, both oncological and
mechanical. Previous studies have reported that curettage
of single metastatic lesions in the pelvis is associated with
high mortality and decreased survival compared with wide
resection and have justified consideration of a radical surgical
approach to achieve tumor control [8–14]. Surgery is probably
one of the most important aspects of multimodal strategy
in patients with few metastases when a curative attempt is
made possible. Despite the emergence of molecular targeted
systemic therapy (angiogenesis inhibitors formetastatic renal
cell carcinoma) cure is uncommonly achieved in the absence
of surgical resection [15].
The Enneking zones 1 and 3 do not require any recon-
struction following the tumor resection because the ambula-
tion capability is still preserved. A reinforcement by synthetic
mesh helps to avoid visceral herniation. Relatively thin skin,
diminished subcutaneous tissue, and lack of muscle mass
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Figure 2: Indications for surgical and conservative treatment according to the patient classes.
Table 1: Characteristics of the different patient classes comparing metastatic lesions in long bones and pelvis.
Class Long bones Pelvis
1
Solitary metastatic lesion
Primary with good prognosis
(well-differentiated thyroid, prostate, breast sensitive to adjuvants, rectum, clear-cell renal, lymphoma, and myeloma)
Interval over three years since detection of the primary
2 Pathological fracture at any site Pathological fracture in periacetabular region
3 Impending fracture in a major weight bearing bone Supra-acetabular osteolytic lesion
4
Multiple osteoblastic lesions at all sites Multiple osteoblastic lesions at all sites
Osteolytic or mixed lesions in nonstructural bone Osteolytic or mixed lesions in iliac wing and anterior pelvis
Osteolytic lesion with no impending fracture in major
weight bearing bone Small periacetabular osteolytic lesions
overlying the anterior part of the pelvis increase the risk for
skin necrosis and wound complications [1].
Resections in zone 2 alone or in combination with the
adjacent regions necessitate further reconstruction to prevent
disability and gait disturbances. The periacetabular region
can be replaced by custom-made ormodularmegaprosthesis,
saddle prosthesis, or massive allograft in combination with a
total hip replacement (Figure 3).
The saddle prosthesis (Link, Hamburg, Germany) was
designed by Nieder et al. [16] for large acetabular defects in
revision hip arthroplasty. Since the 1908s the saddle pros-
thesis was also used for reconstruction after periacetabular
tumor resection. A notch has to be created in the iliac rem-
nant, in some cases with an allograft augmentation providing
more stability. The saddle articulates with the iliac notch
and does not require an exact anatomic fit. A high risk of
complications (ranging from 33 to 65%) are reported [12, 17,
18].Themajor complications consist of wound problems (18–
37%), transient peroneal nerve paresis, and neuropraxia of
the sciatic and femoral nerves because of the manipulation
of the femur and fractures of the remaining iliac wing (0–
7%), which generate leg length discrepancies and dislocations
(0–18%). The long-term functional outcome was poor with
limited hip flexion [18].
Therefore the saddle prosthesis cannot be recommended
for reconstruction after periacetabular tumor resections and
remains a salvage procedure for extreme cases.
Custom-made and modular megaprostheses are useful
in cases in which standard components are not sufficient.
Intraoperative still modifiable modular components (espe-
cially the anteversion of the femoral neck) help to achieve
better stability of the hip joint. The few available data in the
literature indicates a satisfying functional outcome: most of
the reported patients can ambulate without pain [19].
Wide tumor resections in the pelvis are reported to
have a high rate of complications. But skeletal metastases
decrease the quality of life, especially the loss of mobility,
independence, and social functioning of a patient [20]. In
spite of the mentioned complications, the surgical treatment
of pelvic metastasis improves significantly the quality of life
and morbidity of the patients [21, 22]. The decision to expose
the patient to the burden of major surgery should be well
considered and restricted to patients with a good prognosis
and major functional impairments.
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Figure 3: Different reconstruction techniques after wide resection of a periacetabular lesion. (a) Megaprosthesis; (b) saddle prosthesis; (c)
massive allograft with total hip replacement.
6. Patient Classes 2 and 3
Impending and pathological fractures necessitating a surgical
intervention are all located in the periacetabular region
(Enneking zone 2). The principle goal of the surgical treat-
ment is to prevent a pathological fracture (Class 3) or to
restore the mechanical integrity and function (in partic-
ular ambulation) if the fracture already occurred (Class
2). Preoperative angiography and selective embolization are
recommended in highly vascular lesions such as clear-cell
renal or thyroid carcinoma. If wide oncological margins
are achieved at resection, postoperative radiotherapy can
be avoided, but it is still recommended after marginal or
intralesional procedures or in patients presenting with a
pathological fracture. It should be delivered with full doses
(3000 to 5000 cGy) and not with levels used for palliative
control of pain.
The amount of the periacetabular bone loss dictates
the type of surgery. A good tool to indicate the acetabular
destruction is the Harrington Classification, ranging from
Groups I to IV (Figure 4).
Harrington Group I. If the subchondral bone of the acetab-
ulum is still intact, a simple curettage of the lesion may
be performed with cement filling, thus preserving the hip.
This procedure may be even carried out percutaneously.
Metal pins or bars inserted into intact bone may be used as
augmentation to reinforce the acetabular dome. Often the
normal congruity of the acetabular surface shows already
a disruption. But the unaffected periacetabular bone is still
sufficient for a cemented conventional hip prosthesis. The
incidence of loosening and migration will not exceed the
amount seen in routine total hip replacement. Porous-coated
implants have the disadvantage of requiring bone ingrowth
for stability. These implants should not be used as the
ingrowth is impaired by the cancer and chemo- or radiation
therapy applied postoperatively.
Harrington Group II. The medial wall of the acetabulum is
destroyed but the superior part (roof) and the lateral wall is
still preserved. The use of a conventional prosthesis would
lead to a medial migration and consequent loosening.There-
fore the cup has to be fixed with the help of a reinforcement
ring; otherwise the reconstruction will fail (Figure 5).
Harrington Group III. Extensive osteolysis affects not only the
medial wall but also the roof and the lateral rim of the acetab-
ulum. In most patients also the inferior part is functionally
nonexistent. So there is no possibility to adequately fixate
a conventional cup or a reinforcement ring. Reconstruction
typically involves using an implant and cement with internal
fixation that extends into uninvolved portions of the pelvis.
The large defect has to be replaced first by cement or
an allograft to allow an implantation of a cup component
afterwards. The use of cement is preferable as the addition of
antibiotic drugs lowers the infection risk and an immediate
weight-bearing of the affected limb is possible. The disease of
the host bone and the irradiation therapy impair the union
and ingrowth of an allograft postoperatively. Pseudarthrosis,
allograft fractures, prolonged functional impairments, and a
higher infection rates are resulting.
Harrington described a technique [23] using large
threaded pins placed within the surrounding hemipelvis to
support the cemented acetabular component. These pins are
used to transform the weight-bearing stresses from the com-
ponent placed in the deficient acetabular bone to the unaf-
fected bone of the remaining pelvis (Figure 6).This technique
is challenging and requires an understanding of the pelvic
anatomy and spatial orientation. Placing a finger in the sciatic
notch while drilling helps to orientate the anteroposterior
pins and protects the sciatic nerve.
Every effort must be made to improve stability of the hip
and to avoid subsequent dislocation. Intrinsically stable joints
should be implanted if possible. The use of either a snap-fit
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Figure 4: Classification of acetabular defects according to Harrington. (a) Integrity of medial and superior periacetabular bone (Group I).
(b) Medial wall insufficiency (Group II). (c) Medial wall and supra-acetabular destruction (Group III). Group IV (no image): total collapse
of acetabulum.
Figure 5: Pre- and postoperative radiographies for Harrington Class 2 bone defect.
Figure 6: Pre- and postoperative radiographies of Class 3 acetabular defect using the Harrington technique for reconstruction.
6 Advances in Orthopedics
Table 2: Summary of surgical techniques for pelvic metastasis.
Patient Site oflesion Resection Reconstruction
Class 1
Zones 1, 3 Widemargins None
Zone 2 Widemargins
Harrington procedure
Megaprosthesis
Saddle prosthesis
Massive allograft with
THR
Harrington I defect
Curettage, cement
Conventional THR
Harrington II defect
THR with reinforcement ring
Harrington III defect
Classes
2, 3 Zone 2
Marginal,
intralesional
Harrington procedure
Defect filling with cement or
allograft and THR
Harrington IV defect
Megaprosthesis
Saddle prosthesis
Massive allograft with
THR
THR: total hip replacement.
socket or a large prosthetic femoral head (size 28 to 32mm)
is strongly recommended.
Harrington Group IV.Theacetabulum is collapsed completely
and can be restored only through a resection. The used
reconstructions techniques are the same as in Class 1 patients
except that aiming for wide margins is not necessary.
A summary of the different reconstruction techniques
and their indications is shown in Table 2.
7. Suggestion for Surgical Treatment in
Classes 2 and 3
Concordant tometastatic lesions in long bones [7] an adapted
scoring system is introduced for assessment of periacetabular
metastases in patients belonging to Class 2 or 3 (Table 3).
Additionally to the size of defect, the expected survival
(Table 4) and the response of the tumor to adjuvant treatment
(Table 5) were taken into account. The aim of the scoring
system is selecting the most appropriate surgery to avoid
over- or undertreatment of the metastatic lesions. The surgi-
cal treatment should be more aggressive in an expected long
survival of the patient and big lesions, which do not improve
during adjuvant therapies.
8. Patients Class 4
This class includes patients with multiple osteoblastic lesions
at any site and osteolytic or mixed lesions in non-weight-
bearing bones (Enneking zones 1 and 3) who do not match
the criteria for Class 1. Patients in Class 4 should be treated
conservatively by chemotherapy, hormonal therapy, and/or
irradiation according to the diagnosis. Periacetabular lesions
(Enneking zone 2) can be treated in the same way if they
are osteoblastic or osteolytic with a small size and a positive
reaction to irradiation is expected (breast, thyroid, prostate,
myeloma, and lymphoma). Weight-bearing is strictly forbid-
den during the radiation therapy to reduce the risk for an
iatrogenic fracture [24]. The response to treatment and the
control of pain should be carefully evaluated at follow-up. In
the case of pathological fracture, persistence of pain for two
months after completion of treatment [25], or radiological
signs of local progression, the patients should be referred to
an orthopedic surgeon for surgical treatment since they are
now in either Class 2 or Class 3.
9. Minimally Invasive Treatment
Patients evaluated as Class 4 do not benefit from a sur-
gical resection of the metastatic lesion. They are treated
conservatively trying to improve quality of life. Radiation
therapy is quite effective in providing relief from painful
bonemetastasis: 50–80%of patients experience improvement
in their pain and 20–50% of the treated patients have even
complete pain relief [26, 27]. So the external irradiation is
the standard care for patients with localized bone pain and
results in the palliation of the majority of these patients.
However, some patients do not experience any pain relief.
Furthermore, patients who have recurrent pain at a site
previously irradiatedmay not be eligible for further radiation
therapy secondary to limitations in normal tissue tolerance.
Image-guided percutaneous methods of tumor destruction
have rapidly evolved for benign skeletal lesions and more
recently for palliation of painful bone metastasis. Because of
shortcomings of the currently available therapies for painful
metastatic disease, there is a need for alternative treatment
strategies. All these new techniques are based on the use
of percutaneous image-guided methods to deliver tissue
ablative materials or devices inside the metastatic lesion. In
the literature described procedures are the local application
of ethanol, laser-induced interstitial thermotherapy, cryoab-
lation, and radiofrequency ablation. Additionally a new and
promising technology is the electrochemotherapy, but it is
still under investigation for the efficacy in bone metastasis
and the clinical application [28, 29]. These percutaneous
treatments should be considered if the patient has pain
not controllable by narcotic analgesics or not responding to
earlier applied therapies and is not eligible for a surgical
resection. The device based ablation methods may also be
combined with the use of methyl methacrylate for further
stabilization.
9.1. Ethanol and Thermotherapy. The easiest and presumably
the most cost-effective treatment is the injection of ethanol
(95%) under CT guidance [30]. The rare existing reported
results in the literature indicate a complete pain relief in 16%
andno effect in 28%of the patients [30]. For the laser-induced
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Table 3: Scoring system and recommended treatment for pelvic metastasis in patients of classes 2 and 3.
Survival Site of defect Size of defect Response to adjuvant therapy
<1 year = 1
Periacetabular = 1
Small supra-acetabular or medial wall = 2 Yes = 0
1-2 years = 2 Medial and lateral wall = 4 No = 3
>2 years = 3 Protrusio acetabuli = 6
Up to 5 points: curettage or conventional total hip replacement
5 to 10 points: complex total hip replacement (reinforcement ring, Harrington procedure)
10 to 13 points: megaprosthesis, saddle prosthesis, and massive allograft
Table 4: Predictive survival and scoring for the protocol.
Survival Source of metastasis
<1 year (1 point)
Unknown
Melanoma
Lung
Pancreas
Thyroid (undifferentiated)
Stomach
1 to 2 years (2 points)
Colon
Breast (not responding to adjuvants)
Liver
Uterus (responding to adjuvants)
Over 2 years (3 points)
Thyroid (differentiated)
Myeloma
Lymphoma
Breast (responding to adjuvants)
Rectum
Prostate
Kidney
Table 5: Predictive response to adjuvant treatment and scoring for
the protocol.
Responsive to adjuvant therapy
(0 points)
Breast
Thyroid
Myeloma
Lymphoma
Prostate
Nonresponsive to adjuvant therapy
(3 points)
Kidney
Gastrointestinal tumor
Lung
Uterus
Pancreas
thermotherapy only 3 cases are reported with a pain relief of
maximal 45% [31].
9.2. Cryoablation. Cryoablation has a long history of success-
ful treatment of neoplasms in several organs, especially in
the prostate. The rapid freezing adjacent to the probe results
in intracellular ice formation and with more distance to the
probe the cooling causes osmotic differences. Both of these
cellular changes induce cell death. Available preliminary
data suggest that cryoablation is effective in treating painful
secondary bone neoplasms [32, 33].
9.3. Radiofrequency Ablation. Radiofrequency ablation uti-
lizes a high-frequency alternating current that is passed from
the needle electrode into the surrounding tissue, resulting
in frictional heating and necrosis. Dupuy [34] first reported
that radiofrequency ablation ofmetastases involving the bone
may provide pain relief. The first results were engaging and a
multicenter study was performed [35] to obtain reliable data:
95% of the included patients experienced a clinical significant
pain reduction during the observed time.
9.4. Promising New Technique: Electrochemotherapy. Elec-
trochemotherapy (ECT) is the combined effect of electric
fields and chemotherapeutics to treat tumor [29]. Using
electric pulses bleomycin can enter the tumor cells and
accumulates intracellularly. A local effect is created without
any unspecific toxicity to normal tissue. Clinical application
of ECT mainly focuses on cutaneous and subcutaneous
metastatic tumor nodules. Laboratory findings in rats suggest
good clinical and histological results using electrochemother-
apy in bone metastasis [28]. No important side effects were
observed and it seems that in contrary to the other ablation
techniques the mechanical bone strength is preserved. Fur-
ther clinical investigations have to be performed to evaluate
this promising procedure.
9.5. Acetabuloplasty. Cotten et al. [36] adapted the verte-
broplasty technique and applied the same principles for
the management of secondary osteolytic lesions around
the acetabulum. Acetabuloplasty consists of a percutaneous
injection of low viscosity acrylic cement into the osteolytic
cavity (Figure 7).
The principal goal is an immediate improvement of
the mechanical properties of the affected bone, especially a
higher resistance to compressive stresses lowering the frac-
ture risk [37]. Additionally the exothermic reaction during
the polymerization of the cements exerts a local cytotoxic
reaction against the tumor. Complete pain relief is achieved
in 59% of patients [38].The combination between an ablation
therapy and cementoplasty seems to boost the overall effect.
A 100% success rate concerning pain control was reported for
radiofrequency ablation together with cementoplasty at the
level of the spine [39].
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Table 6: Overview for reported results in minimally invasive techniques.
Technique Author Year Patients Follow-up Complications Effect
Ethanol therapy Gangi et al. [30] 1994 25 2 weeks none Complete pain relief in 16%
Partial pain relief in 75%
Laser-induced
thermotherapy Groenemeyer et al. [31] 2002 3 3 months none 45% pain reduction
Cryoablation Callstrom et al. [33] 2006 14 6 months none Pain relief in 100%
Radiofrequency
ablation
Goetz et al. [35] 2004 43 16 weeks
1 skin burn
Pain relief in 95%
1 transient bowel and
bladder
incontinence (metastasis of
sacrum)
1 fracture of acetabulum
Acetabuloplasty
Cotten et al. [36] 1995 18 7 months Recurrent pain Pain relief in 81%fever/inflammatory
processes
Marcy et al. [40] 2000 18 4.6 months 1 acetabular fracture Pain relief in 81%
Hierholzer et al. [41] 2003 5 — None Pain relief in 100%
Kelekis et al. [42] 2005 14 — 1 intraarticular leakage Pain relief in 92%1 leakage near pudendal
nerve
Maccauro et al. [38] 2008 25 6 months 2 venous injection ofcement
Complete pain relief in 59%
Partial pain relief in 49%
Figure 7: Intra- and postoperative radiographies of an acetabuloplasty.
Generally very low complication rates are observed using
the percutaneous procedures. Due to the minimal skin
incision infection risk is very low. Rare cases of cement
protrusion in the hip joint are described with no significant
functional loss [40, 42]. Ablation methods as radiofrequency
or cryotherapy are contraindicated if the tumor is closer than
1 cm to important structures, for example, spinal cord, major
nerves, vessels, or intestine. A short overview for the reported
results of minimally invasive techniques is shown in Table 6.
10. Conclusion
Pelvic bone metastases are a growing concern in the field of
orthopedic surgery. Every patient needs careful evaluation
and staging. Wide resection results in an improved survival
only in solitary metastasis with favorable prognosis. Oste-
olytic lesions in the periacetabular regions can lead to
pathological fractures and important functional impairment.
Different reconstruction techniques for the acetabulum are
available; the choice depends on the patient’s prognosis, size
of the bone defect, and response of the tumor to adjuvant
treatment. Osteosclerotic acetabular lesions and lesions in
the iliac wing and the anterior pelvis are commonly treated
conservatively with external irradiation to reduce pain and as
local control. If all the conservative treatments are exhausted
and the patient is not eligible for surgery, a percutaneous
ablation therapy with radiofrequency or cryoablation can
be considered. Cementoplasty is another minimal invasive
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solution to reduce pain and additionally to reinforce the
residual bone.
Every patient needs his individual treatment of themetas-
tasis to provide the best possible life quality despite the
advanced stage of disease. A good organized collaboration
between the different specialists as oncologists, radiation
therapist, and orthopedic surgeon is mandatory. The use of
the presented classifications and algorithms simplifies the
teamwork and helps to avoid under- or overtreatment of
pelvic bone metastasis.
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